Free Trial
John Stansel

John Stansel Analyst Performance

Healthcare Services Equity Research at J.P. Morgan at JPMorgan Chase & Co.

John Stansel is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 4 publicly traded companies. Over the past year, John Stansel has issued 11 stock ratings, including buy and hold recommendations. While full access to John Stansel's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Stansel's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
11 Last 0 Years
Buy Recommendations
36.36% 4 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy36.4%4 ratings
Hold63.6%7 ratings
Sell0.0%0 ratings

Out of 11 total stock ratings issued by John Stansel at JPMorgan Chase & Co., the majority (63.6%) have been Hold recommendations, followed by 36.4% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
2 companies
NASDAQ
50.0% of companies on NASDAQ
2 companies

John Stansel, an analyst at JPMorgan Chase & Co., currently covers 4 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

John Stansel of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - HMO
2 companies
50.0%
MED/DENTAL - SUPP
1 company
25.0%
MEDICAL SERVICES
1 company
25.0%

John Stansel's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Centene Corporation stock logo
CNC
Centene
5/5/2026Boost Price Target$53.59$52.00Neutral
Centene Corporation stock logo
CNC
Centene
3/19/2026Lower Price Target$35.57$41.00Neutral
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2/25/2026Boost Price Target$81.57$92.00Overweight
Alignment Healthcare, Inc. stock logo
ALHC
Alignment Healthcare
2/5/2026Boost Price Target$21.30$26.00Overweight
Centene Corporation stock logo
CNC
Centene
1/22/2026Boost Price Target$45.25$45.00Neutral
Alignment Healthcare, Inc. stock logo
ALHC
Alignment Healthcare
11/24/2025Upgrade$16.70$20.00Overweight
Henry Schein, Inc. stock logo
HSIC
Henry Schein
11/5/2025Boost Price Target$71.84$78.00Overweight
Centene Corporation stock logo
CNC
Centene
11/4/2025Boost Price Target$35.78$38.00Neutral
Molina Healthcare, Inc stock logo
MOH
Molina Healthcare
7/29/2025Lower Price Target$166.60$184.00Neutral
Centene Corporation stock logo
CNC
Centene
7/29/2025Lower Price Target$26.36$30.00Neutral
Centene Corporation stock logo
CNC
Centene
7/2/2025Reiterated Rating$56.68$48.00Neutral